BioinforMatrix

PubMeth: Reviewed Methylation Database

Pubmeth is an annotated and reviewed database of methylation in cancer. It is based on automated textmining of literature and is afterwards manually curated and annotated.

TreeIllustrator: the new standard in Phylogenetic Tree Visualisation

TreeIllustrator is quickly becoming the standard program for displaying and manipulating phylogenetic trees. It gives you powerful means to customise your phylogenetic trees and compare them with the current classification of organisms.

BioZendium: the peer-reviewed Bioinformatics Wiki

Biozendium aims to provide layered access for our students and researchers, but also for the external community, to the knowledge present in our laboratory; to create an (inter)active community of people who are interesting to or interested in the Bioinformatics subject; to motivate students to learn Bioinformatics more actively by contributing to this digital knowledge base.

Biotech Hobbyist Magazine

Biotech Hobbyist Magazine is a magazine tailored specifically for the biotech enthusiast. We recognise that some of the greatest cultural and technological advances have emerged from peoples bedrooms and are therefore committed to transferring the hitech life sciences to the bedroom biotechnician. We are looking forward to offering a range of exciting projects, informative product reviews and fun competitions.

ProteinCenter� Open Access; Lookup protein accession codes and peptides

Proxeon releases free public lookup of proteins and tryptic peptides; The ProteinCenter� Open Access. Lookup protein accession codes and peptides in a global database with more than 22 million protein accession codes. One single resource for lookup of any protein accession codes and identifiers from: GenBank, Refseq, EMBL, UniProt, Swiss-Prot, Trembl, PIR, IPI, PDB, Ensembl etc. Including many of the outdated accession codes. Overview annotation for the protein in the ProteinCard, including mapping of accession codes, GO, disease, pathway annotation, sequence features etc. It also includes very fast retrieval of richly annotated BLAST neighbors. Lookup tryptic peptide(s) to see all proteins including the given peptides (6-32 AA and no miscleavages) Try ProteinCenter� Open Access The ProteinCenter� Open Access is part of the complete ProteinCenter� solution. The single protein lookup in ProteinCenter� Open Access is a small subset of the full functionality provided by the commercial version of ProteinCenter�, which takes you to a completely new discovery level, enabling comparison of data sets with thousands of proteins in minutes, with advanced clustering and filtering to quickly reach biological conclusions. ProteinCenter� integrates the contents of a large number of public protein sequence databases and your experimental systems biology data. It provides a number of bioinformatics tools, and much more, to be the most comprehensive bioinformatics analysis tool available for any scientist who looks at protein and sequence information. ProteinCenter� for example enables comparing multiple data sets of thousands of proteins in minutes. Get the true overlap, independently of the original database source. Import analytical results from leading international scientific studies and see your data in a new context. Data sets can be mined, compared and documented in a matter of minutes using a range of truly novel methods for handling large proteomics data sets. Learn more about ProteinCenter�

ONCOMETHYLOME SCIENCES TO PARTICIPATE IN AN INTERNATIONAL CLINICAL TRIAL TO OPTI

OncoMethylome Sciences to Provide MGMT Gene Methylation Testing in a Phase III Clinical Trial for Patients with Brain Tumors, Conducted Jointly by the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer.

DURHAM, NC (USA) and LIEGE (BELGIUM) ― April 5, 2006 ― OncoMethylome Sciences announced today that it will perform MGMT gene methylation testing for a multi-center clinical trial for patients with brain tumors conducted jointly by the U.S.-based Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). With patient enrollment underway, the trial was designed to determine whether increasing the intensity of temozolomide drug treatment regimen for patients with glioblastoma multiforme tumors improves clinical outcomes over standard-dose temozolomide. This phase III trial brings together a valuable network of international medical centers and universities and is the first such collaborative study between RTOG and EORTC organizations.

Kakuro - the new puzzle on the block

Kakuro is a new puzzle game taking over the world in storm.

It started in the UK at the guardian :
guardian UK

and you can see people playing Kakuro on the tube in UK everyday.

here're some kakuro links :

kakuro - play online

http://games.groups.yahoo.com/group/kakuro - kakuro message group

http://en.wikipedia.org/wiki/Kakuro - learn more info

If you liked sudoku you'll love sudoku, I'm already addicted, have fun :-)

Frost & Sullivan lauds AlgoNomics' Technology Innovation

London, 24th April 2006 -- Frost & Sullivan presents the 2006 Technology Innovation Award in the field of structural bioinformatics for drug discovery to Belgium-based AlgoNomics NV for its pioneering Epibase� technology platform. Offering an innovative and efficient method of identifying T-cell epitopes, this platform has the potential to challenge current sequence-based methodologies.

�A platform for T-cell epitope identification, Epibase� analyses whether therapeutic protein leads show an increased risk for immunogenicity and helps researchers optimise protein leads,� say Frost & Sullivan Research Analysts Ravi Shankar and Srimathy Raghuraman. �In other words, AlgoNomics� technology helps researchers avoid lengthy, expensive and overlapping peptide studies.�

An in silico platform, Epibase� assists the drug development process at different stages. Researchers use this technology to compare the immunogenecity of drug leads where they compare the T-cell epitope content of large numbers of protein variants entering the drug development stage. By identifying the T-cell epitopes at the research level, certain drug leads can be rejected during the early stages of drug development. This facilitates the selection of the most promising protein leads and also helps in the removal of the epitopes while optimising the proteins.

In cases where HLA alleles are linked with diseases, Epibase� enables the exploration of drug candidates to check if they are safe for the targeted patient population. It identifies new T-cell epitopes based on structural bioinformatics and covers a broad range of HLA subtypes, such as the CTL and humoral responses. Further, it is also able to produce a high throughput on computer clusters. Moreover, Epibase� does not rely on public databases as did earlier tools such as Bimas, Tepitope, Epimatrix or Propred.

�Vis-�-vis peptide synthesis and HLA presentation experiments, Epibase� performs much faster screening and provides more cost-effective information delivery,� note Mr. Shankar and Ms. Raghuraman. �More importantly, Epibase� helps researchers avoid lengthy, expensive overlapping peptide studies, which translates into cost reductions of over 100.000 euro per protein analysed, and a gain in speed of two weeks when compared to the typical three to six months needed for traditional tests.

AlgoNomics� focus on structural bioinformatics R&D � which yielded this groundbreaking technology platform � will continue, with the company working on HLA subtypes with impact in countries such as China, India, Indonesia, and Japan, as well as the Hispanic and Black-American population groups.

AlgoNomics collaborates with a wide range of companies such as Cambridge Antibody Technologies, Genmab, GSK, Evogenix, J&J Tibotec, Innogenetics, Ablynx, Bayer Cropscience, and Evolutec.

The Frost & Sullivan Award for Technology Innovation is presented each year to the company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change and competitive posture.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About AlgoNomics

AlgoNomics is a Belgium based biotech company that provides structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics offers in silico support to companies that develop rationally designed vaccines and therapeutic proteins.
AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains biologically validated, innovative tools, which have been developed in-house.
AlgoNomics� premier product is the Epibase� platform for T-cell epitope identification in different population groups.

For more information about AlgoNomics and Epibase� visit www.algonomics.com or contact

AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent � Belgium
Tel.: +32.(0)9.241.11.00
Fax.: +32.(0)9.241.11.02
Philippe.Stas@algonomics.com

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com or contact

Frost & Sullivan
Kristina Menzefricke
Promotions Manager, Best Practices � EMEA
+44 (0) 207 343 8376
kristina.menzefricke@frost.com

BiotechIndustryStocks.com, Biotechnology Investor Portal, Adds To Online Content

BiotechIndustryStocks.com, Biotechnology Investor Portal, Adds To Online Content with New Service: News and Article Submission for Biotech Companies

POINT ROBERTS, Wash., Delta, B.C. � April 27, 2006 � www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector, announces a new service for public and private companies to submit press releases to online visitors following the industry. In addition, BiotechIndustryStocks.com has added a new feature for freelance journalists and industry experts to contribute articles. The new content will build upon the highly visited portal articles, written by in-house writers and well known financial journalist Michael Brush. Additionally the site features audio interviews, stock directories, audio conferences, blogs, RSS feeds and links.

BiotechIndustryStocks.com Content Submission Pages:

To submit Biotech news to be read by investors and industry following the biotech sector: http://www.biotechindustrystocks.com/NewsUploader/

To submit Biotech articles to be read by investors and industry following the biotechnology sector: http://www.biotechindustrystocks.com/NewsUploader/Submit_Article/

About BiotechIndustryStocks.com
www.BiotechIndustryStocks.com, a portal within the InvestorIdeas.com � content umbrella, is an investor and industry news portal for the Biotech and Pharma sector. The website does not make recommendations, but offers a unique free information portal to research news, exclusive articles, interviews, investor conferences and a growing list of participating public companies in the sector.

Additionally the site features a growing directory of Biotech Stocks: http://www.investorideas.com/Research/Biotech,PharmaStocks.asp

Additional Investor Content within the InvestorIdeas.com � content umbrella:

Investor Incite Newsletter
InvestorIdeas.com� free "Investor Incite" newsletter consists of company and industry updates, investment research and developing trends in key areas such as Homeland Security, Renewable Energy, Biotech, Oil and Gas and more. To sign up, click here: www.InvestorIdeas.com/Resources/Newsletter.asp

The "Insiders Corner": Insiders Corner by Michael Brush offers analysis of significant insider purchases at small-cap and micro-cap stocks
http://www.investorideas.com/insiderscorner/

Investor Online Audio Conferences: Online audio presentations with public companies and industry experts
http://www.investorideas.com/forums/

InvestorIdeas.com� Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. These sites are currently compensated for by "featured companies."

For more information contact:

Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Ann Marie Fleming: 866-725-2554 - afleming@investorideas.com

Agency Takes a Preliminary Step to Revoke a Genentech Patent

In a preliminary ruling, patent examiners said Genentech's claims represented "double-patenting," meaning the new patent, awarded in 2001, covered basically the same invention as an earlier Genentech patent that was set to expire next March.